StockData

Keros Therapeutics vs Viridian Therapeutics, Inc.\DE

KROS and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KROS and VRDN compare

Viridian Therapeutics, Inc.\DE is the larger company, worth 15 times as much as Keros Therapeutics ($3.4B against $224M).

Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −93.7% for Keros Therapeutics).

Viridian Therapeutics, Inc.\DE keeps more of each dollar of sales as profit, with a net margin of −544% compared with −572% at Keros Therapeutics.

Keros Therapeutics scores higher on the StockData Score (7 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKROSVRDN
Size and price
Market cap$224M$3.4B
Share price$11.31$30.06
Change, 1 year−34.5%4.5%
Change, 5 years−79.8%64.3%
Beta (5Y)2.04−0.13
Employees78252
StockData Score
Total score7 (better)4
Valuation score1 (better)0
Growth score02 (better)
Performance score11
Health score5 (better)1
Dividend score00
Valuation
P/S15.4× (better)47.9×
P/B0.9× (better)5.1×
FCF yield−21.6%−9.8% (better)
Fair value–$8.47
Margin of safety–−255%
Growth
Revenue growth (TTM)−93.7%23220% (better)
Revenue growth, 5Y average–132%
Net income growth (TTM)−543%–
EPS growth (TTM)−1287%–
Profitability
Operating margin−698%−570% (better)
Net margin−572%−544% (better)
FCF margin−334% (better)−471%
Return on equity−17.2% (better)−65.7%
Return on invested capital−755%–
Financial health
Debt / equity0.00–
Interest coverage–−26.0×
Current ratio21.96 (better)16.95
Altman Z-score2.67 (better)2.65
Piotroski F-score6 (better)4
Dividends and buybacks
Buyback yield–−1.7%
Shareholder yield0.00% (better)−1.7%
Ownership
Held by institutions101%120%
Held by insiders53.3%21.8%
Insider net buying, 12 months−$453K$19.6M (better)
Short interest, % of float11.7%19.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.